Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview

• Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery market size has reached to $4.96 billion in 2025 • Expected to grow to $11.91 billion in 2030 at a compound annual growth rate (CAGR) of 19.1% • Growth Driver: The Increasing Adoption Of Targeted Gene Therapies Driving The Growth Of The Market Due To Advances In Gene Delivery Technologies • Market Trend: Engineered Viral Capsid Innovations Driving More Efficient, Targeted, And Safer Gene Delivery In Advanced Therapeutic Applications • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?

Next-generation adeno-associated virus (AAV) gene therapy delivery refers to advanced vector systems that use engineered AAV capsids to improve the precision, efficiency, and safety of delivering therapeutic genes into target cells. These next-generation platforms are designed to enhance tissue targeting, reduce immune responses, and enable more durable gene expression compared to traditional AAV-based gene therapy approaches. The main types of next-generation adeno-associated virus (AAV) gene therapy delivery include recombinant adeno associated virus, engineered capsid adeno associated virus, and self complementary adeno associated virus. Recombinant adeno associated virus refers to a genetically modified viral vector designed to safely deliver therapeutic genes into target cells for long-term gene expression with minimal pathogenicity. These vectors support in vivo delivery, ex vivo delivery, systemic delivery, and localized delivery methods and are administered through intravenous, intrathecal, intramuscular, and intravitreal routes. The various applications involved are neuromuscular disorders, ophthalmologic diseases, cardiovascular gene therapy, and rare metabolic disorders and they are utilized by end users including hospitals, specialty clinics, research institutes, and biopharmaceutical companies.

What Is The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Growth Forecast?

The next-generation adeno-associated virus (AAV) gene therapy delivery market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%.The growth in the forecast period can be attributed to growing adoption of personalized gene therapies, increasing development of advanced AAV vector engineering platforms, rising commercialization of gene therapy products, expanding research in precision medicine applications, growing demand for improved safety and efficacy of genetic treatments. Major trends in the forecast period include increasing adoption of engineered aav capsid technologies for targeted gene delivery, growing development of immune response reduction strategies in aav therapies, rising demand for durable and precise gene expression platforms, expanding applications of next generation aav vectors in rare disease treatments, increasing focus on scalable manufacturing processes for advanced gene therapy vectors.

What Is The Driver Of The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?

The increasing adoption of targeted gene therapies is expected to propel the growth of the next-generation adeno-associated virus gene therapy delivery market going forward. Targeted gene therapies refer to a form of treatment that delivers genetic material to specific cells or tissues in the body to correct or modify disease-causing genes while minimizing effects on non-target cells. Increasing adoption of targeted gene therapies is due to advances in gene delivery technologies that improve precision, safety, and efficiency in delivering therapeutic genes directly to specific cells or tissues. Increasing adoption of targeted gene therapies drives demand for more precise, efficient, and tissue-specific delivery systems, thereby accelerating innovation and refinement in next-generation adeno-associated virus (AAV) gene therapy delivery platforms. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, in the fourth quarter of 2023, the number of gene therapies in Phase III rose by 10% compared to the previous quarter, representing the first increase since the third quarter of 2022. Therefore, the increasing adoption of targeted gene therapies is driving the growth of the next-generation adeno-associated virus gene therapy delivery market.

Key Players In The Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

Major companies operating in the next-generation adeno-associated virus (aav) gene therapy delivery market are Pfizer Inc., Novartis AG, Bayer AG, Astellas Pharma Inc., Sarepta Therapeutics Inc., Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V., Ring Therapeutics, Dyno Therapeutics Inc., Généthon, Sangamo Therapeutics Inc.

Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Trends and Insights

Major companies operating in the next-generation adeno-associated virus gene therapy delivery market are focusing on developing innovative solutions, such as engineered capsids to improve transduction efficiency, reduce required dosing, and enhance overall safety and therapeutic efficacy. Engineered capsids are genetically modified protein shells of adeno-associated viruses (AAVs) designed to improve gene delivery by enhancing tissue targeting, increasing transduction efficiency, and reducing immune recognition. For instance, in May 2026, Affinia Therapeutics, a US-based biotechnology company, presented new preclinical and translational data at a major gene and cell therapy conference, highlighting advances in its AAV gene therapy platform. The update showcased progress in capsid engineering, manufacturing scalability, and clinical trial design aimed at improving targeted gene delivery efficiency. Its lead candidate, AFTX-201, was emphasized for its potential in treating BAG3-associated dilated cardiomyopathy through enhanced cardiac-specific gene expression using a proprietary AAV vector.

What Are Latest Mergers And Acquisitions In The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?

In January 2024, Novartis AG, a Switzerland-based multinational pharmaceutical company focused on innovative medicines and advanced gene therapies, expanded its partnership with Voyager Therapeutics in a deal valued at up to $1.2 billion to develop next-generation gene therapies for neurological diseases. Through this collaboration, Novartis aims to leverage Voyager’s proprietary TRACER adeno-associated virus (AAV) capsid platform to improve central nervous system (CNS) targeting, enhance blood-brain barrier penetration, and enable more efficient gene delivery for diseases such as Huntington’s disease and spinal muscular atrophy. Voyager Therapeutics Inc is a US-based biotechnology company specializing in engineered AAV capsids and gene therapy delivery technologies focused on neurological disorders.

What Defines the Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market?

The next-generation adeno-associated virus (AAV) gene therapy delivery market consists of revenues earned by entities by providing services such as viral vector engineering services, gene delivery optimization services, capsid modification services, targeted gene transfer services, preclinical and clinical development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation adeno-associated virus (AAV) gene therapy delivery market also includes sales of gene delivery platforms, tissue-targeted gene therapy vectors, viral vector manufacturing systems, and adeno-associated virus-based therapeutic delivery products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026?

The next-generation adeno-associated virus (aav) gene therapy delivery market research report is one of a series of new reports from The Business Research Company that provides next-generation adeno-associated virus (aav) gene therapy delivery market statistics, including next-generation adeno-associated virus (aav) gene therapy delivery industry global market size, regional shares, competitors with a next-generation adeno-associated virus (aav) gene therapy delivery market share, detailed next-generation adeno-associated virus (aav) gene therapy delivery market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation adeno-associated virus (aav) gene therapy delivery industry. This next-generation adeno-associated virus (aav) gene therapy delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.